{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T18:13:41Z","timestamp":1789496021478,"version":"build-2803163510"},"reference-count":23,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2019,4,4]],"date-time":"2019-04-04T00:00:00Z","timestamp":1554336000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2019,6]]},"abstract":"<jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To investigate the efficacy and safety of insulin degludec\/liraglutide (IDegLira) versus insulin glargine 100\u2009units\/mL (IGlar U100) as add\u2010on to sodium\u2010glucose co\u2010transporter\u20102 (SGLT2) inhibitor therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>\n                      In this 26\u2010week, phase IIIb, open\u2010label, parallel\u2010group, treat\u2010to\u2010target trial, conducted at 74 sites in 11 countries, insulin\u2010na\u00efve people aged \u226518\u2009years with glycated haemoglobin (HbA1c) 53\u201397 mmol\/mol (7.0\u201311.0%), body mass index 20\u201340\u2009kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      and inadequately controlled type 2 diabetes (T2D) on SGLT2 inhibitor \u00b1 oral antidiabetic drugs were randomized 1:1 to once\u2010daily IDegLira or IGlar U100, both as add\u2010on to existing therapy. The primary endpoint was change in HbA1c from baseline to week 26.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 210 participants were randomized to each treatment arm. Mean HbA1c reductions were 21 mmol\/mol (1.9%\u2010points) with IDegLira and 18 mmol\/mol (1.7%\u2010points) with IGlar U100; confirming non\u2010inferiority (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0001) and superiority of IDegLira (difference in HbA1c change \u20133.90 mmol\/mol; 95% confidence interval [CI] \u20135.45; \u20132.35 (\u22120.36%\u2010points; 95% CI \u20130.50, \u20130.21)). Superiority for IDegLira over IGlar U100 was also confirmed for: body weight (difference\u2009\u22121.92\u2009kg; 95% CI \u20132.64, \u20131.19); severe or blood\u2010glucose\u2010confirmed symptomatic hypoglycaemia (rate ratio 0.42; 95% CI 0.23, 0.75); total daily insulin dose (difference \u221215.37\u2009U; 95% CI \u201319.60, \u221211.13). The overall treatment\u2010emergent adverse event rate was higher with IDegLira as a result of higher increased lipase and nausea rates.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The favourable safety and efficacy profile of IDegLira in people with uncontrolled T2D on SGLT2 inhibitors, and lower weight gain and hypoglycaemia risk versus IGlar U100, suggest that clinicians should consider IDegLira initiation in this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.13666","type":"journal-article","created":{"date-parts":[[2019,2,14]],"date-time":"2019-02-14T02:54:58Z","timestamp":1550112898000},"page":"1399-1408","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["Superior efficacy of insulin degludec\/liraglutide versus insulin glargine U100 as add\u2010on to sodium\u2010glucose co\u2010transporter\u20102 inhibitor therapy: A randomized clinical trial in people with uncontrolled type 2 diabetes"],"prefix":"10.1111","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3986-9630","authenticated-orcid":false,"given":"Athena","family":"Philis\u2010Tsimikas","sequence":"first","affiliation":[{"name":"Scripps Whittier Diabetes Institute  San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liana K.","family":"Billings","sequence":"additional","affiliation":[{"name":"NorthShore University HealthSystem  Skokie Illinois"},{"name":"University of Chicago Pritzker School of Medicine  Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Busch","sequence":"additional","affiliation":[{"name":"Albany Medical Centre  Albany New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristobal Morales","family":"Portillo","sequence":"additional","affiliation":[{"name":"Hospital Virgen Macarena  Seville Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Sahay","sequence":"additional","affiliation":[{"name":"Osmania Medical College  Hyderabad India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Halladin","sequence":"additional","affiliation":[{"name":"Novo Nordisk  S\u00f8borg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Eggert","sequence":"additional","affiliation":[{"name":"Novo Nordisk  S\u00f8borg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamilla","family":"Begtrup","sequence":"additional","affiliation":[{"name":"Novo Nordisk  S\u00f8borg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1794-6551","authenticated-orcid":false,"given":"Stewart","family":"Harris","sequence":"additional","affiliation":[{"name":"Western University  London Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,4,4]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-S008"},{"key":"e_1_2_9_3_1","first-page":"14141","article-title":"Assessing the efficacy and safety of combined DPP\u20104 inhibitor and insulin treatment in patients with type 2 diabetes: a meta\u2010analysis","volume":"8","author":"Chen C","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(14)70174-3"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-0785"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.1252"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-016-0218-3"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-1114"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12892"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/dme.13256"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-017-0236-9"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12782"},{"key":"e_1_2_9_13_1","unstructured":"International Conference of Harmonisation. ICH Harmonised Tripartite Guideline. Good Clinical Practice. In: 1996.https:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E6\/E6_R1_Guideline.pdf. Accessed Feb 1 2019."},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.281053"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-011-9886-7"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/9781118762516"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(16)30267-4"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30023-8"},{"key":"e_1_2_9_19_1","unstructured":"National Institute for Health and Care Excellence (NICE).Type 2 diabetes in adults: management. [NICE guidance].2017;https:\/\/www.nice.org.uk\/guidance\/ng28. Accessed Feb 1 2019."},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.4158\/EP161682.CS"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-1414"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-017-0502-2"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13132"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2012.03605.x"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.13666","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.13666","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.13666","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.13666","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:57:23Z","timestamp":1761872243000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.13666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,4]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["10.1111\/dom.13666"],"URL":"https:\/\/doi.org\/10.1111\/dom.13666","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,4]]},"assertion":[{"value":"2018-11-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-02-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}